Approval of tisagenlecleucel (Kymriah), an anti-CD19 chimeric antigen receptor (CAR) T-cell for pediatric and young adult patients with relapsed/refractory B-ALL, marked a significant milestone [28]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.